Following our initial announcement in April, we’re pleased to share the latest update on the clinical trial investigating low-dose naltrexone (LDN) for people living with ME/CFS and Long Covid.
During the period 1 April to 30 June, the team completed 61 pre-screens, and 36 new participants joined the trial. A third of the total participants have completed the 16 weeks treatment period. Enrolment for the MRI sub-study has been completed (n=50), and half of those have also done the follow-up at imaging the end of the treatment period.
To enhance recruitment, the researchers have started contacting potential participants from Ontario Province, adding to those from British Columbia.